Compass Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $850,000 | $0 | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Operating expenses | $72.8M | $57.5M | $50.4M | $41.7M | $81.9M |
| Cash from operations | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Capital expenditure | $25,000 | $44,000 | $30,000 | $212,000 | $1.6M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M |
Shares outstanding 180.1M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.